trending Market Intelligence /marketintelligence/en/news-insights/trending/yHYgX-qCoOMA8YbL-c0NdQ2 content esgSubNav
In This List

US FDA grants orphan status to miRagen's blood cancer drug

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


US FDA grants orphan status to miRagen's blood cancer drug

The U.S. FDA granted an orphan drug designation to miRagen Therapeutics Inc.'s product candidate MRG-106 for the treatment of mycosis fungoides, the most common form of a type of blood cancer called cutaneous T-cell lymphoma.

MiRagen's two lead product candidates MRG-106 and MRG-201 are currently in phase 1 clinical trials.